Excellence in Quality: The Foundation of HTL Biotechnology’s Pharma-Grade Biopolymers

Marie-Armelle Floc’h, Chief of Quality and Regulatory Affairs at HTL Biotechnology, highlights how HTL Biotechnology’s compelling portfolio of pharmaceutical-grade biopolymers is built on uncompromising quality standards; standards that have enabled the company to supply biopolymers for over 30 years without a single batch recall, firmly establishing its reputation for reliability and excellence. 

What distinguishes HTL Biotechnology’s biopolymer platforms in the market today?

HTL Biotechnology has built its reputation on delivering pharmaceutical grade biopolymers, such as Hyaluronic Acid, Polynucleotides and now Recombinant Collagen, with unmatched purity and consistency. Since its founding in 1992, the company has focused on premium quality positioning. With more than 30 years of expertise, we guarantee pharmaceutical-grade biopolymers of exceptional purity and consistency to our clients. 

We have had no batch recalls in 30 years — a record that underlines the rigor and reliability embedded in our processes. This is made possible by our fully integrated GMP manufacturing site in France, where production, quality control, and regulatory expertise operate seamlessly together. In close connection with our global R&D teams, this integration enables us to support our clients throughout their entire product development journey, from early innovation to worldwide commercialization.  

What international standards or certifications does HTL Biotechnology adhere to, to ensure quality, safety, and consistency across its global operations?

Our operations are guided by internationally recognized standards, including ISO 13485 certification, which ensures the quality and safety required by medical device manufacturers worldwide. In addition, our Halal certification provides our customers with a significant advantage in accessing and expanding into markets, where these requirements are essential for commercialization. Beyond certifications, our commitment to supporting global growth is reflected in the Drug Master Files we maintain across five continents, enabling our clients to accelerate product registration and bring innovative therapies to markets across the world more efficiently. 

By combining craftsmanship with pharmaceutical rigor, supported by state-of-the-art equipment and advanced bioproduction methods, we ensure that every batch produced not only meets the strictest standards but also delivers the reliability and the consistency needed across the entire healthcare ecosystem. 

Navigating the complex and evolving regulatory frameworks across global markets can be challenging for healthcare companies. Can you tell us more about how HTL Biotechnology supports its partners in this area?

Regulatory support is part of our core premium services offer. We provide pharmaceutical regulatory support to ensure products meet the necessary compliance standards, so our partners can focus on their growth. Our dedicated regulatory professionals bring global and regional expertise, with a team specifically supporting customers in Asia. 

We offer personalized assistance adapted to their products and to the compliance standards of the target market. This includes personalized case-management support for regulatory file submissions with the concerned health authorities to minimize risks of refusal or delay, with the aim of achieving approval quickly and smoothly. 

Our offer for regulatory support continues beyond approval. We continuously monitor updates to regulations and provide post-commercialization support to our partners to help them manage any necessary regulatory updates.